Clinical trials: Type 2 Diabetes Mellitus
Type 2 Diabetes Mellitus, Coronary Artery Disease
Aspirin Dosing in Diabetic Patients
Since diabetic platelets are characterized by an enhanced turnover rate, it may be hypothesized that an increase in the frequency, rather than the dose, of drug administration may be a more effective strategy to inhibit platelet…
- Trial name
- NCT01201785
- Testing
- Aspirin
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- University of Florida
Xerostomia Due to Hyposecretion of Salivary Gland, Diabetes Mellitus, Type 2
The Artificial Saliva Spray Reduces Xerostomia in Diabetes Type II
In diabetes Type II the xerostomia is a quite frequent symptom. In evaluating the activity of an artificial saliva spray compared to a water gel in patients with Diabetes Type II patients had to follow a three day treatment with…
- Trial name
- NCT03452085
- Testing
- artificial saliva spray (AS), maritime throat spray (TT)
- Where
- Italy
- Volunteers
- 21 people
- Sponsor
- Certmedica International GmbH
Obesity, Weight Reduction
Low-Dose Semaglutide for Weight Loss in Obese Non-Diabetic Pakistani Adults
This prospective, open-label, single-arm, single-center interventional pilot trial aims to evaluate the efficacy and safety of low-dose semaglutide for weight loss and cardiometabolic improvement in obese Pakistani adults without…
- Conditions
- Obesity, Weight Reduction, Cardiometabolic Risk Factors
- Trial name
- NCT07513168
- Testing
- Locally available low-dose semaglutide (0.25 mg, 0.5 mg, 1 mg)
- Where
- Pakistan
- Volunteers
- 60 people
- Sponsor
- Asian Institute Of Medical Sciences
Obesity, Overweight
A Study of LY3549492 in Adults With Obesity or Overweight With Type 2 Diabetes
The main purpose of this study, performed under the master protocol W8M-MC-CWMM (NCT06143956), is to evaluate the effects of treatment with LY3549492 compared to placebo in adult participants with obesity or who are overweight…
- Conditions
- Obesity, Overweight, Type 2 Diabetes
- Trial name
- NCT07030868
- Testing
- LY3549492
- Where
- 42 sites in United States, Argentina
- Volunteers
- 1 people
- Sponsor
- Eli Lilly and Company
Diabetes Mellitus, Type 2
A Study to Evaluate the Effect of LY2189265 on the Speed at Which Food and Drink Leaves the Stomach in Patients With Type 2 Diabetes Mellitus
The primary purpose of this Study is to help answer the following research question(s). How does LY2189265 affect gastric emptying (the speed at which food and drink leaves the stomach) in patients with Type 2 diabetes? How does…
- Trial name
- NCT01215968
- Testing
- LY2189265
- Where
- United Kingdom
- Volunteers
- 38 people
- Sponsor
- Eli Lilly and Company
Diabetes Mellitus Type 2
The Effect of Acipimox on GLP (Glucagon-like Peptide)-1 Secretion
Glucagon like peptide 1 is produced in enteroendocrine L cells in the small intestine stimulated by peroral food intake. GLP-1 induces insulin secretion, and analogues are used in the treatment of DM2 (type 2 diabetes mellitus).
- Trial name
- NCT02796950
- Testing
- Acipimox
- Where
- Denmark
- Volunteers
- 8 people, healthy volunteers welcome
- Sponsor
- University of Aarhus
Type 2 Diabetes, Metabolic Dysfunction-Associated Steatotic Liver Disease
Liver Fibrosis Assessment in Diabetic Patients
The investigators plan to use the smartphone App for FIB-4 calculation and increase the awareness of liver fibrosis. These patients might notify and discuss with the physician of their liver fibrosis severity to improve the…
- Trial name
- NCT06694974
- Testing
- APP calculation for FIB-4, Standard Care (in control arm)
- Where
- Taiwan
- Volunteers
- 540 people
- Sponsor
- National Taiwan University Hospital
Type 2 Diabetes
A Safety Study of ARRY-403 in Patients With Type 2 Diabetes
This is a Phase 1 study, involving a 1-day dosing period, designed to test the safety of investigational study drug ARRY-403 in patients with Type 2 diabetes. Approximately 36 patients from the US will be enrolled in this study.
- Trial name
- NCT00859755
- Testing
- ARRY-403, glucokinase activator; oral
- Where
- United States
- Volunteers
- 41 people
- Sponsor
- Array BioPharma
Diabetes, Diabetes Mellitus, Type 2
Comparing the Efficacy and Safety of NN1250 Once Daily When Titrated Using 2 Different Algorithms in Insulin naïve Subjects With Type 2 Diabetes Mellitus
This trial is conducted in Europe and the United States of America (USA). The aim of this trial is to compare the efficacy and safety of NN1250 (insulin degludec (IDeg)) once daily in insulin naïve subjects with type 2 diabetes…
- Trial name
- BEGIN™ (NCT01326026)
- Testing
- insulin degludec
- Where
- 45 sites in United States, Finland and 2 more
- Volunteers
- 222 people
- Sponsor
- Novo Nordisk A/S
Diabetes Mellitus, Type 2, Implant Complication
Posterior Narrow Diameter Implants in Hyperglycemic and Normo-glycemic Patients
The aim of the present study was to compare the initial healing and long term performance of narrow diameter implants in patients with uncontrolled Diabetes mellitus type 2 (T2DM) and healthy individuals.
- Trial name
- NCT04630691
- Testing
- Implantation
- Volunteers
- 35 people
- Sponsor
- University of Witten/Herdecke
Healthy, Diabetes Type 2
Assessment of Three Instruments for the Non-invasive Measurement of Arterial Stiffness.
The ASI Non-Invasive Arterial Stiffness Screening Device (ASI Device) is an investigational device under development for the non-invasive assessment of arterial stiffness.
- Conditions
- Healthy, Diabetes Type 2, Obesity, Coronary Artery Disease
- Trial name
- ASI-2012 (NCT01722474)
- Testing
- ASI Device
- Where
- Canada
- Volunteers
- 15 people, healthy volunteers welcome
- Sponsor
- University of Manitoba
Critical Lower Limb Ischemia, Type-2 Diabetes Mellitus
Safety and Efficacy Study of Autologous Bone Marrow Aspirate Concentrate for No-Option Critical Limb Ischemia
The aim of the presented clinical trial is to evaluate a hypothesis, that BMAC prepared from bone marrow aspirate and injected intramuscularly into ischemic areas of the lower extremity in patients with diabetes mellitus type…
- Trial name
- DIALEG (NCT01818310)
- Testing
- Group A: Intramuscular, Group B: Intraarterial, Group C: Intravenous
- Where
- Czechia
- Volunteers
- 80 people
- Sponsor
- University Hospital Ostrava
Overweight and Obesity
Assessment of an Intervention to Prevent Obesity and Diabetes in Latino Farm Workers
This is a study to assess the effectiveness of a culturally appropriate behavioral intervention to reduce obesity levels and ultimately the risk of developing diabetes type II in immigrant Latino farm workers.
- Trial name
- Pasos (NCT01855282)
- Testing
- Behavioral Intervention
- Where
- 2 sites in United States
- Volunteers
- 254 people, healthy volunteers welcome
- Sponsor
- University of California, Davis
Type 2 Diabetes Mellitus
Stepping-down Approach in Patients With Chronic Poorly-controlled Diabetes on Advanced Insulin Therapy?
In traditional step-up approach, the patients with poorly-controlled type 2 diabetes are instructed to take up to 4 insulin injections daily or multiple daily injections (MDI) as the most advanced therapy.
- Trial name
- NCT02846233
- Testing
- GLP1 receptor agonist, basal insulin, SGLT2 inhibitor
- Where
- United States
- Volunteers
- 22 people
- Sponsor
- University of California, San Francisco
Type 2 Diabetes Mellitus (T2DM), Diabetes Distress
Achieving Routine Intervention and Screening for Emotional Health
The purpose of this project is to evaluate the effectiveness of diabetes distress screening and intervention on patients with type 2 diabetes mellitus (T2DM).
- Trial name
- ARISE (NCT06887049)
- Testing
- ARISE Learning Community Diabetes Distress Screening and Intervention, ARISE Enhanced Care brief training
- Where
- United States
- Volunteers
- 880 people
- Sponsor
- University of Chicago
Type 2 Diabetes Mellitus
Impact Evaluation of a Mobile Health App to Improve Self-control and Health Outcomes of Patients With Type 2 Diabetes Mellitus (T2DM): Pilot Study "NOVAME"
The objective of this project is to evaluate the effectiveness and cost effectiveness of a health app (NOVAME) designed to improve the self-control of patients with T2DM and their health outcomes.
- Trial name
- NOVAME (NCT03663738)
- Testing
- mobile app NOVAME
- Where
- Spain
- Volunteers
- 199 people
- Sponsor
- Servicio Canario de Salud
Type2 Diabetes, Obesity
Time RestrIcted Feeding For Improving Diabetes Risk (TRIFFID)
This study will explore the effects of eight weeks of time-restricted feeding (TRF) on body weight and composition, glycaemic control, 24-hour glucose profiles, glucoregulatory hormones, and cardiovascular risk in men at high…
- Trial name
- TRIFFID (NCT03590158)
- Testing
- TRF
- Where
- Australia
- Volunteers
- 15 people, healthy volunteers welcome
- Sponsor
- University of Adelaide
Diabetes
Personalized Management of Type 2 Diabetes Using AI-Guided (GenAIS TM) Dietary Supplementation
This randomized controlled trial investigates the effectiveness of AI-guided dietary supplement prescriptions compared to standard physician-guided prescriptions in managing Type 2 diabetes (T2D).
- Trial name
- NCT06469658
- Testing
- The standard practice dietary supplements intervention, The AI-guided practice dietary supplements group
- Where
- Russia
- Volunteers
- 160 people
- Sponsor
- S.LAB (SOLOWAYS)
SGLT-2 Inhibitor, Atrial Fibrillation
The Effect of SGLT-2 Inhibitor in Patient With Atrial Fibrillation and Diabetes Mellitus
This study was designed to compare the effects on atrial rhythm control between SGLT2 inhibitor and other oral hypoglycemic agents in patients with atrial fibrillation and diabetes mellitus.
- Conditions
- SGLT-2 Inhibitor, Atrial Fibrillation, Diabetes Mellitus, Type 2
- Trial name
- NCT05029115
- Testing
- SGLT2 inhibitor
- Where
- South Korea
- Volunteers
- 716 people
- Sponsor
- Ewha Womans University Mokdong Hospital
Type 2 Diabetes
Blood Glucose Response to Highly Viscous Polysaccharide Enriched Biscuits in Healthy and Diabetic Subjects
Our objective was to test whether the highly viscous polysaccharide incorporated into the biscuit formulation would reduce the postprandial blood glucose response equally in healthy subjects and individuals with type 2 diabetes.
- Trial name
- NCT00728143
- Testing
- Highly viscous polysaccharide enriched biscuits
- Volunteers
- 19 people, healthy volunteers welcome
- Sponsor
- Unity Health Toronto